The Genomics of Cerebral Palsy
Are Copy Number Variants associated with Cerebral Palsy?

A thesis submitted for the degree of Master of Philosophy to the University of Adelaide

By

Gai McMichael

School of Paediatrics and Reproductive Health

Discipline of Obstetrics and Gynaecology

November 2011
Statement of Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the test.

I give consent to this copy of my thesis, when deposited in the University Library, being available for loan and photocopying.

Gai Lisette McMichael

November 2011
Acknowledgments

I extend my thanks to my primary supervisor, Professor Alastair MacLennan for his support and guidance over the duration of this study. His mentoring and encouragement to me personally and in my career thus far has provided me with many valuable and exciting opportunities for which I am extremely thankful. It has been an absolute pleasure to work alongside Professor MacLennan and to share this experience with him. I feel very privileged to have had Professor MacLennan as my principle supervisor and I look forward to the future with him as my continual mentor and colleague.

I gratefully extend my thanks to my co-supervisors Dr Jillian Nicholls and Dr Catherine Gibson. I extend sincere thanks to Dr Nicholls for her excellent technical guidance and her enthusiasm towards this project. I very much appreciated Dr Nicholls continuing support and availability throughout this project of which I could not have completed without her.

I give my thanks to Dr Catherine Gibson who has been a longstanding colleague. Her support and encouragement over the years has been invaluable. I am very thankful for Dr Gibson’s eye to detail particularly when reading this thesis, her past research expertise and knowledge of Cerebral Palsy.

It would not have been possible to complete this work without my three supervisors.
I am very appreciative of the support and expertise of our four international collaborators on this project. Firstly to Professor Christa Martin and Dr Andres Moreno De Luca from Emory University School of Medicine for processing our samples on the custom-designed 180K array. Thank you to Professor Evan Eichler and Dr Santhosh Girirajan from the University Of Washington School Of Medicine for processing the same samples on the custom-designed 135K array. I sincerely thank our four collaborators for their willingness to share their invaluable knowledge and expertise. This project would not have been possible without their contribution.

There were a number of staff at the Neurogenetics Research Department at the Women’s and Children’s Hospital who offered assistance throughout this project whom I would like to thank. In particular I extend many thanks to Professor Jozef Gecz whose technical advice and knowledge of the development of the human brain was invaluable. Thank you to Sonny Nguyen and Stanley Tan for their assistance in Taqman assays. Thank you to staff at SA Pathology in particular Dr Kathryn Friend for her assistance with DNA extractions.

I would also like to extend my thanks to the Department of Clinical Genetics, in particular to Professor Eric Haan for his invaluable clinical expertise throughout this project.

I am very appreciative and thankful for the support from the Department of Paediatric Rehabilitation Medicine in particular, Dr Ray Russo, Dr James Rice and Dr
Andrew Tidemann for allowing us to collect blood samples whilst our participants are under general anaesthetic.

Thank you to the staff at the Department of Obstetrics and Gynaecology, both at the Women’s and Children’s Hospital and the Medical School for supporting me through this candidature.

To the members of the Australian Cerebral Palsy Research Group, my thanks for their help and support. A special thanks to Corinne Reynolds for her administrative support throughout this thesis.

This work has been supported by the Cerebral Palsy Alliance Research Foundation, University of Adelaide, Women’s and Children’s Research Foundation and National Health and Medical Research Council.

Finally, I extend a very special thank you to my four beautiful daughters whose continual love and support in all that I undertake sees me through to the finish line.
Contents

Statement of Declaration ............................................................................................................................................. i
Acknowledgments ..................................................................................................................................................... ii
Contents ..................................................................................................................................................................... v
List of Tables .......................................................................................................................................................... vii
List of Figures .......................................................................................................................................................... viii
Abstract .................................................................................................................................................................... xiii
Chapter 1 Literature Review ................................................................................................................................. xvi
  1.1 Introduction ....................................................................................................................................................... 1
    1.1.1 Cerebral Palsy ................................................................................................................................................. 1
    1.1.2 Prevalence of Cerebral Palsy ......................................................................................................................... 2
    1.1.3 Risk factors for Cerebral Palsy ....................................................................................................................... 3
    1.1.4 Intrauterine Infection ..................................................................................................................................... 4
    1.1.5 Cytokines ......................................................................................................................................................... 5
    1.1.6 Thrombophilia .................................................................................................................................................. 6
    1.1.7 Apolipoprotein E .............................................................................................................................................. 7
    1.1.8 Genomic Progress ......................................................................................................................................... 8
    1.1.9 Copy number variants .................................................................................................................................... 9
    1.1.10 Platforms for assessing copy number variations ....................................................................................... 11
    1.1.11 Autism .......................................................................................................................................................... 13
    1.1.12 Schizophrenia .............................................................................................................................................. 14
    1.1.13 Intellectual disability ................................................................................................................................. 15
    1.1.14 Epilepsy ......................................................................................................................................................... 16
    1.1.15 Cerebral Palsy and copy number variants ............................................................................................... 17
    1.1.16 Conclusion .................................................................................................................................................... 19
  1.2 Hypothesis and Aims ........................................................................................................................................ 21
    1.2.1 Hypothesis ................................................................................................................................................... 21
    1.2.2 Aims/Objectives of the project .................................................................................................................... 21
Chapter 2 Cohort Demographics ............................................................................................................................. 22
  2.1 Cohort Demographics ...................................................................................................................................... 23
    2.1.1 Study Cohort .................................................................................................................................................. 23
    2.1.2 Cerebral Palsy Cohort Clinical Characteristics .......................................................................................... 23
    2.1.3 Cerebral palsy subtype ................................................................................................................................ 24
Chapter 3 Materials and Methods

3.1 Methodology .......................................................................................................................... 37
   3.1.1 Study Design .................................................................................................................... 37
   3.1.2 Recruitment of cerebral palsy families ............................................................................ 37
   3.1.3 Blood collection .............................................................................................................. 47
   3.1.4 Lymphocyte cell line development .................................................................................. 47
   3.1.5 DNA extraction .............................................................................................................. 48
   3.1.6 DNA quantification from LCLs and blood ....................................................................... 49
   3.1.7 Array Comparative Genome Hybridization (array-CGH) ............................................... 49

3.2 Part A – Custom-design 180K microarray .............................................................................. 50
   3.2.1 CNV discovery ................................................................................................................. 50
   3.2.2 Sample labelling and hybridization .................................................................................. 51
   3.2.3 Analysis/Filtering ............................................................................................................. 51

3.3 Part B – Custom-design 135K microarray .............................................................................. 51
   3.3.1 CNV discovery ................................................................................................................. 51
   3.3.2 Sample labelling and hybridization .................................................................................. 52
   3.3.3 Analyses/Filtering ............................................................................................................ 53
   3.3.4 Determining candidate regions for cerebral palsy from both array-CGH platforms ...... 53
   3.3.5 CNV validation and mode of transmission by qPCR for both array-CGH platforms ........ 54

Chapter 4 Results .......................................................................................................................... 47

4.1 Results ...................................................................................................................................... 48
   4.1.1 DNA quantification from LCLs and blood ....................................................................... 48

4.2 Part A – Custom-designed 180K microarray ......................................................................... 49
   4.2.1 Figures 4.1, 4.2 and 4.3 ..................................................................................................... 52

4.3 Part B – Custom-designed 135K microarray ......................................................................... 58
   4.3.1 CNV burden analyses for cerebral palsy ........................................................................ 64
   4.3.2 CNV burden analysis for cerebral palsy ......................................................................... 65
4.3.3 Results from Taqman assays ........................................... 66

Chapter 5 Discussion ..................................................................... 80

5.1 Discussion ............................................................................ 81

5.1.1 Family CP36 – CTNN2 ..................................................... 81

5.1.2 Family CP25 – MCPH1 ...................................................... 83

5.1.3 Family CP20 – COPS3 ....................................................... 84

5.1.4 Microarray platform comparisons ....................................... 89

5.1.5 Limitations of this study .................................................... 90

5.1.6 Future directions ............................................................... 91

Chapter 6 Conclusions .................................................................. 93

6.1 Conclusions ........................................................................ 94

Chapter 7 References ................................................................... 94

7.1.1 References ...................................................................... 97

Chapter 8 Supplementary Data .................................................... 107

8.1 Supplementary data ............................................................ 107

List of Tables

Table 2.1 Type of cerebral palsy. .................................................. 24
Table 2.2 Gestational age distribution of cerebral palsy cohort. .......... 26
Table 2.3 Birth weight distribution of cerebral palsy cohort ............... 28
Table 2.4 Co-morbidities distribution of cerebral palsy cohort .......... 30
Table 2.5 Gender distribution of cerebral palsy cohort .................... 32
Table 4.1 Summary of CNVs from custom design 180K microarray .... 50
Table 4.2 CNVs unique to one individual in CP cohort (custom-designed 180K array). 51
Table 4.3 CNVs in Gene - Locus regions (custom designed 180K microarray). 56
Table 4.4 Summary of CNVs from custom-designed 135K microarray. 58
Table 4.5 CNVs unique to one individual in CP cohort (custom-designed 135K microarray). 59
Table 4.6 CNVs in gene-locus regions (custom-designed 135K microarray) 60
Table 4.7 Results of Taqman assays. ........................................... 66
Table 4.8 Information on gene-locus regions. .............................. 68
Table 4.9 Combined Genetic and Clinical data for each individual CP case. 72
Table 8.1 Quantification results for EBV transformed cell lines ......... 107
Table 8.2 Quantification results for DNA maxi preps. ...................... 108
Table 8.3 Quantification results for DNA mini preps ....................... 108
Table 8.4 All CNV calls .............................................................. 109
List of Figures

Figure 2.1 Type of cerebral palsy in our cohort of 50 cases. .......................................................... 25
Figure 2.2 Gestational age distribution of babies with cerebral palsy compared with Pregnancy Outcome Unit South Australia data (POSU). ................................................................................. 27
Figure 2.3 Birth weight distribution of babies with cerebral palsy compared with Pregnancy Outcome Unit South Australia data (POSU). ................................................................. 29
Figure 2.4 Co-morbidities distribution of cerebral palsy cohort. .................................................... 31
Figure 2.5 Gender distribution of cerebral palsy cohort. ............................................................... 33
Figure 3.1 Letter of invitation for Cerebral Palsy Research project ............................................. 40
Figure 3.2 University of Adelaide Information Sheet. ............................................................... 41
Figure 3.3 University of Adelaide consent form. ........................................................................... 42
Figure 3.4 Genetic Repositories Australia information sheet. ...................................................... 43
Figure 3.5 Genetic Repositories Australia Consent Forms. ............................................................ 44
Figure 3.6 Participant Health Background Questionnaire ............................................................... 45
Figure 4.1 CTNND2 Snapshot of gene location on Chr 5 including probe coverage (14). .......... 53
Figure 4.2 MCPH1 Snapshot of gene location on Chr 8 including probe coverage (66). ......... 54
Figure 4.3 COPS3 Snapshot of gene location on Chr 17 including probe coverage (13). .......... 55
Figure 4.4 CNV burden analysis for cerebral palsy shows the population frequency of the largest CNVs (as a survivor function) in individuals with cerebral palsy compared to 337 controls from the National Institute of Mental Health (NIMH) cohort\textsuperscript{140}. The frequency of the large CNVs is not vastly different between the two groups. .............................................................. 65
Figure 4.5 A broader comparison in cerebral palsy to CNV data from individuals with ID, autism, dyslexia, and controls\textsuperscript{140}. Note that all the samples were analysed using the same hotspot chip. ............................................................................................................................................. 65
HUGO Gene Nomenclature gene symbol and gene name.

ABCC1 - ATP-binding cassette, sub-family C (CFTR/MRP), member 1
ADAMTS13 - ADAM metallopeptidase with thrombospondin type 1 motif, 13
AGRN - agrin
CACNA1H - calcium channel, voltage-dependent, T type, alpha 1H subunit
CHRNA4 - cholinergic receptor, nicotinic, alpha 4
CHAT - choline O-acetyltransferase
CNTN1 - contactin 1
CNTNAP3 - contactin associated protein-like 3
COPS3 - COP9 constitutive photomorphogenic homolog subunit 3
CTNND2 - catenin (cadherin-associated protein)
C16orf62 - chromosome 16 open reading frame 62
DHCR7 - 7-dehydrocholesterol reductase
DLGAP2 - discs, large (Drosophila) homolog-associated protein 2
FLRT3 - fibronectin leucine rich transmembrane protein
FSCB - fibrous sheath CABYR binding protein
GABRD - gamma-aminobutyric acid (GABA) A receptor, delta
INPP5E – inositol polyphosphate-5-phosphatase, 72 kDa
KCNMB3 – potassium large conductance calcium-activated channel
KCNQ2 - potassium voltage-gated channel
MACROD2 - MACRO domain containing 2
MC2R - melanocortin 2 receptor (adrenocorticotropin hormone)
MCPH1 - microcephalin 1
HUGO Gene Nomenclature Committee approved gene symbol and gene name
MPV17L – MPV17 mitochondrial membrane protein-like
MYO5B - myosin VB
### HUGO Gene Nomenclature (continued)

<table>
<thead>
<tr>
<th>Gene Symbol</th>
<th>Gene Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NBEA</td>
<td>neurobeachin</td>
</tr>
<tr>
<td>NCOR2</td>
<td>nuclear receptor corepressor 2</td>
</tr>
<tr>
<td>NF1</td>
<td>neurofibromin 1</td>
</tr>
<tr>
<td>NIPA1</td>
<td>non imprinted in Prader-Willi/Angelman syndrome 1</td>
</tr>
<tr>
<td>NOS3</td>
<td>nitric oxide synthase 3 (endothelial cell)</td>
</tr>
<tr>
<td>NPHP1</td>
<td>nephronophthisis 1 (juvenile)</td>
</tr>
<tr>
<td>PAK2</td>
<td>p21 protein (Cdc42/Rac)-activated kinase 2</td>
</tr>
<tr>
<td>PARK2</td>
<td>parkinson protein 2, E3 ubiquitin protein ligase (parkin)</td>
</tr>
<tr>
<td>PCDH11X</td>
<td>protocadherin 11 X-linked</td>
</tr>
<tr>
<td>PNKP</td>
<td>polynucleotide kinase 3'-phosphatase</td>
</tr>
<tr>
<td>PRAME</td>
<td>preferentially expressed antigen in melanoma</td>
</tr>
<tr>
<td>PRODH</td>
<td>proline dehydrogenase (oxidase) 1</td>
</tr>
<tr>
<td>PTCHD3</td>
<td>proline dehydrogenase (oxidase) 1</td>
</tr>
<tr>
<td>SHANK2</td>
<td>SH3 and multiple ankyrin repeat domains 2</td>
</tr>
<tr>
<td>SHANK3</td>
<td>SH3 and multiple ankyrin repeat domains 3</td>
</tr>
<tr>
<td>SH3GL3</td>
<td>SH3-domain GRB2-like 3</td>
</tr>
<tr>
<td>SLC6A1</td>
<td>solute carrier family 6 (neurotransmitter transporter, GABA), member 1</td>
</tr>
<tr>
<td>SLC6A3</td>
<td>solute carrier family 6 (neurotransmitter transporter, dopamine), member 3</td>
</tr>
<tr>
<td>SLC6A11</td>
<td>solute carrier family 6 (neurotransmitter transporter, GABA), member 11</td>
</tr>
<tr>
<td>SLC25A22</td>
<td>solute carrier family 25 (mitochondrial carrier: glutamate), member 22</td>
</tr>
<tr>
<td>SORCS2</td>
<td>sortilin-related VPS10 domain containing receptor 2</td>
</tr>
<tr>
<td>TBX1</td>
<td>T-box 1</td>
</tr>
<tr>
<td>TSPAN7</td>
<td>tetraspanin 7</td>
</tr>
<tr>
<td>UGT2B</td>
<td>UDP glucuronosyltransferase 2 family, polypeptide B4</td>
</tr>
<tr>
<td>UROC1</td>
<td>urocanase domain containing 1</td>
</tr>
</tbody>
</table>
Abbreviations

CP – Cerebral Palsy

CNVs – Copy number variants

DGV – Database of Genomic Variants

CHOP – Children’s Hospital of Philadelphia database

OMIM – Online Mendelian Inheritance of Man

UCSC – University of California Santa Cruz

CMV – Cytomegalovirus

EBV – Epstein Barr Virus

IL-4 – Interleukin – 4

MBL – Mannose Binding Lectin

APOE – Apolipoprotein

SNPs – single nucleotide polymorphisms

bps – base pairs

kb – kilo base

NAHR – non allelic homologous recombination

aCGH- array Comparative Genome Hybridization

HMM – Hidden Markov Model

FISH – fluorescent in situ hybridization

qPCR – quantitative real time polymerase reaction

Au – Autism

ASD – Autism Spectrum Disorders

Ep – Epilepsy

ID – Intellectual Disability

JS – Joubertt Syndrome

PLS – Potocki-Lupski Syndrome
**Abbreviations (continued)**

SZ – Schizophrenia
SMS – Smith-Magenis syndrome
TS – Tourette Syndrome
VWD – Von Willebrand Disease
IUGR – Intrauterine growth restriction
ACD – acid citrate dextrose
EDTA – ethylenediaminetetraacetic acid
GRA – Genetic Repositories Australia
LCLs – Lymphoblastoid cell lines

**URLs**

Database of Genomic Variants, [http://proejcts.tcag.ca/variation/](http://proejcts.tcag.ca/variation/)

UCSC Genome Bioinformatics, [http://genome.ucsc.edu/cgi-bin/hgGateway](http://genome.ucsc.edu/cgi-bin/hgGateway)

Decipher database, [https://decipher.sanger.ac.uk/](https://decipher.sanger.ac.uk/)

Abstract

Background Cerebral palsy describes a group of permanent disorders of the development of movement and posture that are attributed to non-progressive disturbances occurring in the developing fetal or infant brain. It is often accompanied by additional features including intellectual disability, autism, epilepsy and visual and hearing impairment. The overall incidence of cerebral palsy has not changed in the last 50 years despite major improvements in perinatal medicine, and remains at around 2-2.5/1,000 deliveries world-wide. Treatment is symptomatic rather than curative. A child under 18 years of age is three times more likely to be diagnosed with cerebral palsy than cancer. There are major social, economic and quality of life issues for both the child with cerebral palsy and their family. In Australia, approximately 600 children are diagnosed with cerebral palsy each year. Several studies have suggested that genetic susceptibility factors and adverse environmental triggers such as perinatal viral infection can act both independently and in combination to contribute to the neuropathology of cerebral palsy. For the majority of cases the exact determinants responsible for injury to the child’s developing brain have not been defined.

This thesis hypothesises that cerebral palsy is genetically highly heterogeneous and caused by many diverse and individually rare mutations of large effect in genes involving brain development, the most common of which are copy number variants (CNVs).

Study design To explore the hypothesis that CNVs contribute to the aetiology of cerebral palsy, 50 DNA samples from individuals with cerebral palsy were tested on a
custom-designed 180K chromosomal microarray with targeted plus whole genome coverage. The targeted coverage includes known clinically relevant regions such as microdeletion/duplication syndromes, telomeres and centromeres at a resolution of \(~20\text{-}50\) kb plus exon-level coverage of \(>1200\) genes involved in neurodevelopmental disorders. The whole-genome backbone results in a resolution in unique DNA of \(~225\)kb. These same samples were also separately assessed on a 135K custom designed array with targeted coverage of \(~50\)kb in all genomic hotspots and backbone coverage of 350kb. Combined results were compared with 8,329 adult controls with no known neurological disorders.

**Results** Three out of 50 cases were identified with a CNV that included candidate genes of special interest for the cerebral palsy phenotype; *CTNND2* (446 kb duplication including the first exon), *MCPH1* (219 kb duplication including exons 1-8) and *COPS* (4 kb deletion including exons 6-8). All three CNVs were shown to be inherited from an unaffected parent. Several additional CNVs of possible interest to the cerebral palsy phenotype were selected from 30 out of 50 cases, including the above three mentioned cases, as they encompassed genes expressed in the brain or were previously recognized in other neurodevelopmental disorders. These included Histone Cluster genes, 7q21 and 12p12.1p12.2, single-gene CNVs across *CNTNAP3, MC2R, FSCB, PTCHD3, NPHP1* and *TARP* and intragenic CNVs in *DLGAP2, PARK2, NBEA, PAK2, MACROD2, CNTN1, MPV17L, NF1, NCOR2, NOS3, SH3G13* and *TBX1*.

**Conclusion** Copy number changes in cerebral palsy cases have been identified in this largest study to date. Amongst 50 cases there were three potential candidate genes
for cerebral palsy and several additional variants involved in brain developmental genes. The pathogenicity of these rare CNVs is not currently resolved but these preliminary studies justify further evaluation of CNVs in a larger cohort of cerebral palsy families and functional studies. This is currently underway.